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Workshop Summary 
Relating inflammatory changes in asthma to 
clinical status 
J. BOUSQUET 
H6pital Arnaud de Villeneuve, Montpellier, France 
The biological basis of chronic airway inflammation and 
the effect of drugs on the inflammatory process have been 
well characterized, as discussed in some of the papers in this 
supplement (l-3). Nevertheless, the correlation of changes 
in inflammatory mediators and cells with changes in clinical 
status requires clarification. Long-term studies are also 
needed to determine whether changes in markers of airway 
remodelling are reflected in altered disease progression and 
clinical outcome. 
Reduction of bronchial inflammation appears to improve 
lung function (4,5), although the exact mechanism is still 
debatable. Furthermore, reduction of immunological re- 
activity in the bronchial wall has been shown to reduce 
bronchial hyperresponsiveness (6) but whether it can also 
reduce predisposition to allergic reactivity has yet to be 
established. Although reductions in inflammatory markers 
observed in bronchial biopsy or other studies may be 
significant at the biochemical or histological level, they may 
not always correlate with changes in clinical endpoints. The 
reciprocal of this may also hold true; in a recent study in 
mild and moderate asthma patients, 4 weeks’ treatment 
with an inhaled corticosteroid improved forced expiratory 
volume in 1 set (FEVi) and peak expiratory flow but did 
not produce large reductions in inflammatory markers (7). 
This poor correlation may be due to the large time 
difference between the alteration in cell numbers or levels 
of inflammatory markers and improvement in clinical 
symptoms (4). An alternative explanation is that the clinical 
presentation of asthma depends on the interplay of a very 
large number of cellular and molecular processes, which 
may be quite different in individual patients. 
Although studies investigate the effects of asthma 
therapy at several different levels, i.e. clinical, physiological, 
immunological, cellular, molecular and genetic, the degree 
of response to treatment at each level varies considerably. 
As the level of measurement becomes more detailed, its 
influence on the clinical phenotype falls. For example, a 
change in a physiological measurement such as FEVi is 
usually a major determinant (~50%) of the total clinical 
presentation, but at the other extreme, the same degree of 
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change in levels of a particular cytokine may make only a 
2-5% contribution to the clinical phenotype. Although it is 
important to know exactly what happens at each level of 
measurement when treating asthma patients, the correla- 
tion between the effects of a drug on a specific inflammatory 
marker and on the clinical status of the patient will be 
limited, or at best variable. 
A consensus was reached by the workshop delegates on 
the assessment criteria (biopsy and other) that should be 
selected to confirm whether a drug has anti-inflammatory 
activity. The two major elements of bronchial inflammation 
that should be evaluated are cellular inflammation and 
structural changes. In addition, bronchial hyperreactivity 
(BHR) should be measured, as it may reflect changes in 
both the other elements. Monitoring the number or severity 
of acute exacerbations is another clinical measure which 
should correlate with inflammatory changes. 
Reductions in the numbers of T cells, eosinophils and 
macrophages in biopsy samples or in bronchoalveolar 
lavage (BAL) should be monitored using immunohisto- 
chemistry. Delegates also supported the use of markers of 
cell activation, for example eotaxin and the expression of its 
specific receptor, CCR3, for eosinophils (8). Better tools are 
required to analyse gene expression and protein synthesis in 
biopsies. In addition to cell numbers, cell function should 
be determined, e.g. degranulation of eosinophils and mast 
cells. An improvement in the reproducibility of cell function 
assays is required to allow better monitoring of the role of 
cells in the inflammatory process. 
The delegates also agreed that measuring the volume of 
the airway sub-mucosa, either by biopsy or computerized 
tomography, would allow mucosal oedema or increase in 
muscle mass to be monitored. Mucosal oedema can be 
quantified by measuring changes in the vascular perme- 
ability to proteins such as albumin or ccz-macroglobulin 
(9,lO). Other changes to bronchial vasculature, such as the 
density or number of blood vessels in the mucosa can be 
measured as described in this supplement (1). The 
epithelium and the basement membrane (BM) are impor- 
tant structural elements of the airway that should be 
assessed. Restoration of epithelial integrity and reduction in 
the amount of matrix proteins in the BM, such as collagen 
and tenascin, may be detected using electron microscopy; 
the production of tenascin may be useful as a surrogate 
marker of BM thickness (1 l), although the relevance of this 
marker has yet to be determined. The surface of the 
bronchial mucosa may be visually examined during 
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bronchoscopy to determine any changes in the macroscopic 
signs of inflammation. 
In conclusion, bronchial biopsy is a powerful tool that we 
can use to directly measure inflammation in airway tissues. 
Other techniques for sampling luminal contents and 
secretions, such as BAL and induced sputum, can comple- 
ment the information obtained from biopsies, from which 
more can be learned about the underlying mechanisms of 
the acute and chronic processes. In addition, inclusion of 
biopsy assessments in clinical trials, particularly when the 
challenges posed by study design are overcome, will help us 
to understand more fully the activity profiles of the drugs 
that we use to treat asthma patients, and to assess the 
potential of promising new anti-inflammatory therapies in 
development. 
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